Damle N K, Doyle L V
Clinical Biology Department, CETUS Corporation, Emeryville, CA 94608.
J Immunol. 1989 Apr 15;142(8):2660-9.
When cultured with IL-2, human lymphoid cells acquire the ability to lyse various NK-resistant tumor targets. Due to their anti-tumor cytolytic effect, clinical trials with IL-2 alone or IL-2 + IL-2-activated killer (IAK) lymphocytes have been undertaken. However, infusion of therapeutically effective doses of IL-2 is associated with the development of systemic toxicity characterized by exaggerated endothelial permeability, also known as vascular leak syndrome. The present study was designed to examine the effects of IAK cells and their secreted products on vascular endothelial permeability by using an in vitro endothelial permeability model in which the flux of FITC-albumin across endothelial cell (EC) monolayers was measured. When endothelial monolayers were exposed to IAK cells for 2 h, significant increases in the transendothelial permeability to albumin were observed. Exposure of EC to lymphocytes cultured in the absence of IL-2 did not induce significant alteration in the endothelial permeability. In addition, neither culture supernatants of IAK cells nor purified recombinant cytokines, including IL-1 beta, IL-2, IL-3, IL-4, IL-6, TNF-alpha, GM-CSF, M-CSF, and IFN-gamma, had any effect on endothelial permeability in this model. Prior activation of EC with TNF-alpha did not alter the increased permeability induced by IAK cells or lack of it by nonactivated lymphocytes. Dexamethasone treatment of IAK cells abolished their anti-tumor cytolytic effect but only partially inhibited their ability to induce increased endothelial permeability. Pretreatment of IAK cells with mAb directed at the CD11a/CD18 (LFA-1) adhesion complex, and that of EC with mAb directed at the ICAM-1 molecule, inhibited the IAK cell-induced increase in endothelial permeability. These results demonstrate that direct cell-to-cell contact between IAK cells and EC is necessary and sufficient to cause increased endothelial permeability in this model system, and may therefore be an important factor contributing to the development of the vascular leak syndrome observed clinically.
当与人白细胞介素-2(IL-2)一起培养时,人淋巴细胞获得了裂解各种自然杀伤细胞(NK)抗性肿瘤靶标的能力。由于其抗肿瘤细胞溶解作用,已经开展了单独使用IL-2或IL-2 + IL-2激活的杀伤细胞(IAK)淋巴细胞的临床试验。然而,输注治疗有效剂量的IL-2会引发全身毒性,其特征为内皮通透性异常增加,也称为血管渗漏综合征。本研究旨在通过使用体外内皮通透性模型来检测IAK细胞及其分泌产物对血管内皮通透性的影响,该模型通过测量异硫氰酸荧光素(FITC)标记的白蛋白穿过内皮细胞(EC)单层的通量来进行。当内皮单层与IAK细胞接触2小时后,观察到白蛋白的跨内皮通透性显著增加。将EC暴露于未添加IL-2培养的淋巴细胞中,并未引起内皮通透性的显著改变。此外,在该模型中,IAK细胞的培养上清液或纯化的重组细胞因子,包括白细胞介素-1β(IL-1β)、IL-2、IL-3、IL-4、IL-6、肿瘤坏死因子-α(TNF-α)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)、巨噬细胞集落刺激因子(M-CSF)和干扰素-γ(IFN-γ),均对内皮通透性没有任何影响。用TNF-α预先激活EC并没有改变IAK细胞诱导的通透性增加,也没有改变未激活淋巴细胞所导致的通透性缺乏。地塞米松处理IAK细胞消除了其抗肿瘤细胞溶解作用,但仅部分抑制了其诱导内皮通透性增加的能力。用针对CD11a/CD18(淋巴细胞功能相关抗原-1,LFA-1)黏附复合物的单克隆抗体预处理IAK细胞,并用针对细胞间黏附分子-1(ICAM-1)分子的单克隆抗体预处理EC,可抑制IAK细胞诱导的内皮通透性增加。这些结果表明,在该模型系统中,IAK细胞与EC之间的直接细胞间接触对于导致内皮通透性增加是必要且充分的,因此可能是临床上观察到的血管渗漏综合征发生的一个重要因素。